Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

13.37
+0.02000.15%
Volume:786.77K
Turnover:10.49M
Market Cap:2.01B
PE:-2.98
High:13.62
Open:13.33
Low:13.04
Close:13.35
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:0.54
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:164.55
PE(LYR):-1.95

Loading ...

Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says

MT Newswires Live
·
Sep 18

Xenon Stock Craters on Drug Trial Setback. Its Failure Could be This Rival's Gain.

Dow Jones
·
Sep 18

Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.

Dow Jones
·
Sep 11

Biohaven Price Target Maintained with a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 11

Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright

TIPRANKS
·
Sep 11

Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James

TIPRANKS
·
Sep 10

Biohaven falls -15.3%

TIPRANKS
·
Sep 10

U.S. Stocks on the MOVE-Lovesac, Hagerty, Biohaven

Reuters
·
Sep 10

Biohaven Drops as US FDA Seeks More BHV-7000 Safety Data

Reuters
·
Sep 10

Top Premarket Decliners

MT Newswires Live
·
Sep 10

Biohaven Shares Down 9.1% Premarket After US FDA Places Partial Clinical Hold on Co's Epilepsy Drug Trial

THOMSON REUTERS
·
Sep 10

Biohaven - Dosing Continues for over 600 Randomized Patients in Bhv-7000 Program - SEC Filing

THOMSON REUTERS
·
Sep 10

Biohaven - FDA Issues Partial Clinical Hold Pausing New Enrollment for Bhv-7000 on Sept 4, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 10

FDA Places Partial Clinical Hold on Biohaven BHV-7000 Epilepsy Trial, Halting New Enrollment

Reuters
·
Sep 10

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says

MT Newswires Live
·
Sep 09

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $19 From $23, Keeps Speculative Risk

MT Newswires Live
·
Sep 08

RBC Downgrades Biohaven to 'sector Perform', Shares Fall

Reuters
·
Sep 08

Biohaven Ltd. : RBC Cuts to Sector Perform from Outperform; Cuts Target Price to $19 from $23

THOMSON REUTERS
·
Sep 08